ATE345788T1 - Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber - Google Patents

Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber

Info

Publication number
ATE345788T1
ATE345788T1 AT02718181T AT02718181T ATE345788T1 AT E345788 T1 ATE345788 T1 AT E345788T1 AT 02718181 T AT02718181 T AT 02718181T AT 02718181 T AT02718181 T AT 02718181T AT E345788 T1 ATE345788 T1 AT E345788T1
Authority
AT
Austria
Prior art keywords
virally induced
treatment
fever
inhibitors
mediated
Prior art date
Application number
AT02718181T
Other languages
English (en)
Inventor
Dorian Bevec
Ute Stroher
Hans-Dieter Klenk
Christian Wallasch
Original Assignee
Dorian Bevec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dorian Bevec filed Critical Dorian Bevec
Application granted granted Critical
Publication of ATE345788T1 publication Critical patent/ATE345788T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02718181T 2001-03-06 2002-03-06 Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber ATE345788T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01105552 2001-03-06
US27464701P 2001-03-12 2001-03-12

Publications (1)

Publication Number Publication Date
ATE345788T1 true ATE345788T1 (de) 2006-12-15

Family

ID=32523996

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02718181T ATE345788T1 (de) 2001-03-06 2002-03-06 Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber

Country Status (5)

Country Link
US (1) US20040122058A1 (de)
EP (1) EP1420778B1 (de)
AT (1) ATE345788T1 (de)
AU (1) AU2002249261A1 (de)
WO (1) WO2002069960A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US7132398B2 (en) 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
NZ546011A (en) 2003-10-21 2009-09-25 Warner Lambert Co Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
DK1691827T3 (da) * 2004-06-25 2009-12-14 Fibrex Medical Res & Dev Gmbh Anvendelse af peptider, der er afledt fra beta-kæden af det humane fibrinogen, til behandlling af shock
US8232240B2 (en) * 2005-02-23 2012-07-31 The Brigham And Women's Hospital, Inc. Inhibitors of enveloped virus infectivity
DE102008010362A1 (de) * 2008-02-18 2009-08-20 Florian Prof. Dr. Lang Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen
JP6189962B2 (ja) 2012-10-09 2017-08-30 ザ プロクター アンド ギャンブル カンパニー 相乗作用する美容成分の組み合わせを特定する方法
US10302630B2 (en) 2012-10-09 2019-05-28 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111529532A (zh) * 2020-05-05 2020-08-14 华中科技大学同济医学院附属协和医院 曲美替尼在制备治疗肺部炎症性疾病药物及促进Tfh细胞分化药物中的应用
EP3912623B1 (de) * 2020-05-20 2024-07-31 Atriva Therapeutics GmbH Pd-0184264 zur behandlung von coronavirus-infektionen und/oder covid-19-cytokin-sturm
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
AU5610398A (en) * 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
WO2000040237A1 (en) * 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
AU3631500A (en) * 1999-03-19 2000-10-09 Du Pont Pharmaceuticals Company N-adamant-1-yl-n'-(4-chlorobenzothiazol-2-yl) urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
AU3761400A (en) * 1999-03-19 2000-10-09 Du Pont Pharmaceuticals Company Amino-thio-acrylonitriles as mek inhibitors

Also Published As

Publication number Publication date
WO2002069960A3 (en) 2003-01-03
AU2002249261A1 (en) 2002-09-19
EP1420778A2 (de) 2004-05-26
US20040122058A1 (en) 2004-06-24
WO2002069960A2 (en) 2002-09-12
EP1420778B1 (de) 2006-11-22

Similar Documents

Publication Publication Date Title
ATE345788T1 (de) Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
NO20021830L (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
NO20052928L (no) Nye kjemiske forbindelser
ATE325612T1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
NO20045247L (no) Nukleosidderivater for behandling av hepatitt C-virusinfeksjon
ATE405840T1 (de) Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
DE60219793D1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
DE602005023587D1 (de) Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
DK1377314T3 (da) Monoklonale antistoffer mod CLFA-proteinet og fremgangsmåder til anvendelse i behandling eller forebyggelse af infektioner
EP3900717C0 (de) Vidofludimus zur verwendung in der behandlung oder prävention von viruserkrankungen
SA520420909B1 (ar) تثبيط بروتين رابط لـ creb (cbp)
ATE336996T1 (de) Verwendung von flavonoid-derivaten zur behandlung von atopischem ekzem
BR112022001025A2 (pt) Inibidores de calicreína plasmática
ATE446514T1 (de) VERWENDUNG VON ßHYPOXIA INDUCIBLE FACTOR 2ALPHAß ZUR BEHANDLUNG VON ßNEONATAL RESPIRATORY DISTRESS SYNDROMEß
EA200702271A1 (ru) Ингибиторы белка микросомального транспорта триглицеридов и секреции апо-в
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
EA202192454A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
DE602006020775D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
ATE443044T1 (de) Tace inhibitoren
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
NO20010140D0 (no) Kjemotakse-inhiberende protein av Staphylo-Coccus (CHIPS) og dets anvendelse
EP4247800C0 (de) N-substituierte 4-(1,3-aryloxazolo-2-yl)phenyl-verbindungen zur behandlung und prophylaxe von hepatitis-b-virusinfektionen
DE60219940D1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties